ABBV vs DHR: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-10.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Danaher Corporation · Healthcare
$195.98
+7.9% upside to fair value
Grade B
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+7.9%).
DHR trades at a lower forward P/E
(37.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DHR |
| Current Price |
$261.07 |
$195.98 |
| Fair Value Estimate |
$264.30 |
$211.54 |
| Upside to Fair Value |
+1.2%
|
+7.9%
|
| Market Cap |
$461.3B |
$138.7B |
| Forward P/E |
128.0x
|
37.8x
|
| EV / EBITDA |
31.0x
|
22.8x
|
| Price / Sales |
7.3x
|
5.6x
|
| Price / FCF |
22.1x
|
26.2x
|
| Revenue Growth YoY |
+12.4%
|
+3.7%
|
| Gross Margin |
70.7%
|
60.7%
|
| Operating Margin |
27.6%
|
21.0%
|
| Return on Equity |
68.0%
|
7.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
3.81%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…
Accumulation Zones
| Metric |
ABBV |
DHR |
| Zone Low |
$198.23 |
$158.66 |
| Zone High |
$224.66 |
$179.81 |
| In Buy Zone? |
No
|
No
|